Changing the malaria treatment protocol policy in Timor-Leste: an examination of context, process, and actors’ involvement

Health Research Policy and Systems

Paul M Kelly²  Fernando Bonaparte¹  Karen Hobday³  Anthony B Zwi⁴  João S Martins⁴ 

[1] Ministry of Health, Dili, Timor-Leste;Population Health Division, ACT Government Health Directorate, Canberra, Australia;Health, Rights and Development (HEARD@UNSW), School of Social Sciences, University of New South Wales, Sydney, Australia;Faculdade de Medicina e Ciências da Saúde, Universidade Nacional Timor Lorosae, Avenida Cidade de Lisboa, Dili, Timor-Leste

关键词: Treatment protocol;    Timor-Leste;    Policy process;    Policy formulation;    Malaria treatment;    Evidence;   

Others  :  809800
DOI  :  10.1186/1478-4505-11-16

 received in 2012-08-10, accepted in 2013-04-30,  发布年份 2013

【 摘 要 】

In 2007 Timor-Leste, a malaria endemic country, changed its Malaria Treatment Protocol for uncomplicated falciparum malaria from sulphadoxine-pyrimethamine to artemether-lumefantrine. The change in treatment policy was based on the rise in morbidity due to malaria and perception of increasing drug resistance. Despite a lack of nationally available evidence on drug resistance, the Ministry of Health decided to change the protocol. The policy process leading to this change was examined through a qualitative study on how the country developed its revised treatment protocol for malaria. This process involved many actors and was led by the Timor-Leste Ministry of Health and the WHO country office. This paper examines the challenges and opportunities identified during this period of treatment protocol change.

【 授权许可】

   
2013 Martins et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ministerio da Saúde Protokol Pengobatan Malaria. 2nd edition. Ministerio da Saúde, RDTL; 2005.
• [2]Ministry of Health. Malaria Treatment Protocol. 3rd edition. Democratic Republic of Timor-Leste: Ministry of Health; 2007.
• [3]Malaria management protocol. 1st edition. Dili, East Timor: Ministry of Health, Dili, East Timor and World Health Organization; 2002.
• [4]Chen N, Baker J, Ezard N, Burns M, Edstein MD, Cheng Q: Short report: molecular evaluation of chloroquine treatment of uncomplicated plasmodium falciparum malaria in east timor. AmJTrop Med Hyg 2002, 67(1):64-66.
• [5]Guidelines for the Treatment of Malaria. Geneva: The World Health Organization; 2006.
• [6]Bloland PB, Ettling M: Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol 1999, 93(1):5-23.
• [7]Martins JS, Zwi AB, Hobday K, Bonaparte F, Kelly PM: The implementation of a new malaria treatment protocol in timor-leste: challenges and constraints. Health Policy Planning 2012, 27(8):677-686.
• [8]Araújo RM: Minister’s Speech: launching of malaria treatment protocol for timor-leste. 3rd edition. 2007.
• [9]Potter S, Subrahmanian R: Conceptualizing policy-related investigation. In Finding Out Fast. Edited by Thomas A, Chataway J, Wuyts M. London: Sage Publications and The Open University; 1998.
• [10]Walt G, Gilson L: Reforming the health sector in developing countries: the central role of policy analysis. Health Policy Planning 1994, 9(4):353-370.
• [11]Durrheim DN, Williams HA, Barnes K, Speare R, Sharp BL: Beyond evidence: retrospective study of factors influencing a malaria treatment policy change in two South African provinces. Critical Public Health 2003, 13(4):309-330.
• [12]Williams HA, Durrheim D, Shretta R: The process of changing national malaria treatment policy: lessons from country level studies. Health Policy Planning 2004, 19(6):356-370.
• [13]Djimde A, Plowe CV, Diop S, Dicko A, Wellems TE, Doumbo O: Use of antimalarial drugs in Mali: policy versus reality. AmJTrop Med Hyg 1998, 59:376-379.
• [14]Talisuna AO, Bloland P, D’Alessandro U: History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004, 17(1):235-254.
• [15]White NJ: Drug resistance in malaria. British Med Bull 1998, 54(3):703-715.
• [16]White NJ: Antimalarial drug resistance. J Clin Investig 2004, 113(8):1084-1092.
• [17]Grbich C: Qualitative data analysis: an introduction. London: SAGE Publications; 2007.
• [18]Patton MQ: Qualitative research & evaluation methods. 3rd edition. Thousand Oaks. London: Sage Publications; 2002.
• [19]Lin K: Meeting Minutes. Malaria Working Group; 2005.
• [20]Palmer GR, Short SD: Health care & public policy: an australian analysis. 3rd edition. South Yara: MacMillan Publishers Australia Pty Ltd; 2003.
• [21]Martins JS, Zwi AB, Kelly PM: Did the first global fund grant (2003–2006) contribute to malaria control and health system strengthening in Timor-Leste? Malar J 2012, 11:237.
• [22]Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN: Tow fixed dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369:757-765.
• [23]Report of the Twenty-Fourth Meeting of Ministers of Health of Countries of the South-East Asia Region. Dhaka, Bangladesh: World Health Organization. New Delhi: WHO Regional Office for South-East Asia; 2006.
• [24]Revised malaria control strategy: focusing on a new paradigm. Thimphu, Bhutan: WHO Regional Office for South-East Asia; 2007.
• [25]Martins JS, Zwi AB, Martins N, Kelly PM: Malaria control in Timor-Leste during a period of political instability: what lessons can be learned? Confl Heal 2009, 3:11.
• [26]Zwi AB, Martins J, Grove NJ, Wayte K, Martins N, Kelly P: Timor-Leste Health Sector Resilience and Performance in a Time of Instability. Sydney: The University of New South Wales; 2007.
• [27]Annual Report Year 3 Program. National Malaria Control Program. Dili: The Ministry of Health, RDTL; 2007.
• [28]Shwe T, Lwin M, Aung S: Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar. Bull World Health Organ 1998, 76(Suppl. 1):35-41.
• [29]Sipilanyambe N, Simon JL, Chanda P, Olumese P, Snow RW, Hamer DH: From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia. Malar J 2008, 7:25.
• [30]Walt G: Health Policy: An Introduction to Process and Power. London and New Jersey: Zed Books; 1994.
• [31]Rungsihirunrat K, Sibley CH, Mungthin M, Na-Bangchang K: Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand. AmJTrop Med Hyg 2008, 78(3):462-467.
• [32]Nair S, Williams JT, Brockman A, Paiphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, Nosten F, Anderson TJ: A selective sweep driven by pyrimethamine treatment in Southeast Asian malaria parasites. Mol Biol Evol 2003, 20(9):1526-1536.
• [33]White NJ, Olliaro PL: Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 1996, 12(10):399-401.
• [34]Amin AA, Zurovac D, Kangawana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW: The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 2007, 6:72.
• [35]Almeida A, Arez AP, Cravo PVL, Rosario VE: Analysis of genetic mutations associated with anti-malarial drug resistance in plasmodium falciparum from the democratic republic of East Timor. Malar J 2009, 8:59.
• [36]Ranson K, Poletti T, Bornemisza O, Sondrop E: Promoting Health Equity in Conflict-Affected Fragile States. The Conflict and Health Program. London: London School of Hygiene and Tropical Medicine; 2007.
• [37]Zwi A, Ugalde A: Towards an epidemiology of political violence in the third world. Soc Sci Med 1989, 28(7):633-642.